Clozapine: (Contraindicated) Keep away from concomitant use of ketoconazole and clozapine on account of an increased danger for torsade de pointes (TdP) and QT/QTc prolongation. Additionally, concomitant use could improve the exposure of clozapine, thereby further growing the chance for opposed events. Clozapine is a CYP3A substrate and ketoconazole is a robust CYP3A inhibitor.
Loperamide: (Contraindicated) Concomitant use of loperamide and ketoconazole is contraindicated as a result of an elevated danger for torsade de pointes (TdP) and QT/QTc prolongation. Concomitant use may additionally increase loperamide exposure and the danger for different loperamide-related hostile effects; loperamide is a CYP3A and P-gp substrate and Buy Subutex Online uk ketoconazole is a robust CYP3A and P-gp inhibitor. Coadministration with another robust CYP3A4 and P-gp inhibitor elevated loperamide publicity by 3.8-fold.
Tamoxifen: (Reasonable) Concomitant use of tamoxifen and ciprofloxacin might enhance the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consider taking steps to reduce the risk of QT/QTc interval prolongation and TdP, corresponding to avoidance, electrolyte monitoring and repletion, and ECG monitoring, particularly in patients with further danger factors for TdP.
Anagrelide: (Moderate) Anagrelide has been shown to inhibit CYP1A2. In principle, coadministration of anagrelide with substrates of CYP1A2, including caffeine, could result in will increase in the serum concentrations of caffeine and, thus, adversarial effects. (Reasonable) Anagrelide is partially metabolized by CYP1A2. Coadministration of anagrelide with medicine that induce CYP1A2, similar to barbiturates, could theoretically increase the elimination of anagrelide and decrease the efficacy of anagrelide.
